

# A Lab Big Data Work Success Story:

Combining Lab, EHR, Operations, Financial, and Other Data  
Now Generating Real-Time Insights to Manage Costs,  
Improve Outcomes, Collect More Revenue

James Pepon, Pathology Division Administrator

Joshua Rivera, Pathology Business Operations Director



# History of Leadership & Innovation

- Established by the Florida Legislature in 1981.
- Named after H. Lee Moffitt, former Speaker of the Florida House.
- Opened in 1986, quickly earning its NCI-designation through innovative, breakthrough research.
- Received our highest score ever by the National Cancer Institute in 2021.
- In 2021, we celebrated 35 years of providing patient care and hope to countless patients and families.



## Our Mission

Since the beginning, our mission has been


**to contribute to the prevention  
and cure of cancer.**





# A Courageous Trajectory

Cancer won't quit. So we can't settle.



# National Recognition


- Once again, awarded the National Cancer Institute’s highest designation – Comprehensive Cancer Center.
- Moffitt is the only NCI Comprehensive Cancer Center based in the state of Florida.
- For the sixth consecutive year, Moffitt has been recognized as a leader in Diversity.





# Moffitt's Expanding Footprint

We devote more than 3 million square feet to research and patient care.



*We've seen patients from:*

- 67 Florida Counties
- 50 States
- 130+ Countries



# 10-Year Campus Plan

*SPEROS FL + Moffitt SouthShore*



## SPEROS FL

This community will become the embodiment of the new digital age of healthcare and a hub for international research and education. The epitome of the next generation of care & research, digitally connected to the community and the world. An epicenter of innovation and a healthcare think tank where thought leaders from around the globe come together. And an anchor where leading edge medicine, pharma, education, research, commerce and wellness intersect.



## MOFFITT AT SOUTHSHORE

Moffitt at SouthShore will focus on a robust radiology program enabling many patients to get imaging done quicker and closer to home. The clinic will treat all cancer diagnoses outside of surgical procedures. It will be staffed with three to five multispecialty medical oncologists, working alongside a few specialty medical and surgical. Moffitt at SouthShore also brings an opportunity to expand clinical trials including trials for breast, lung, gastrointestinal and genitourinary cancers and some blood cancers. Nontherapeutic trials and health outcomes and behavior trials or surveys can also be done at the satellite location.

# FY2023 Clinical Care By The Numbers

We are helping patients find the right diagnosis, treatment and support — all in one place.

**618K+**

Outpatient &  
Screening Visits

**89K+**

Unique Patients  
Seen

**28K+**

New Patients


**13K+**

Surgical Cases






# Current State Pathology Division



Cost Center	Section Name
11200	HLA
11201	Chemistry
11202	Microbiology
11203	Cytology
11204	Hematology
11205	Specimen Processing (SP)
11206	Histology
11207	Lab Administration
11208	Blood Bank
11209	Molecular
11210	Flow Cytometry
11211	FISH/Cytogenetics
11212	MIP Lab
11213	Clinical Test Development
11214	MKC Lab
11215	AP Materials Management
11216	MWC
11217	Advanced Analytical & Digital Lab
11218	MMH Clinical Lab
11219	MMH Histology
11221	MMH Cytology
11222	MMH Blood Bank
11223	Pathology Research Services
17012	Hematopathology Prog Admin
17030	Path Anatomic Prog Admin
46012	Hematopathology
46030	Pathology Anatomic



# Current State Pathology Division *Volumes*



# Current State Pathology Business Intelligence

## Problem Statement



- Pathology currently runs over 170 reports
- Five Main Categories
  - Clinical
  - Financial
  - Quality
  - Research
  - Other
- 14 different sources not including HLA Laboratory (*i.e. Daedulus, Echidna, etc.*)
- Only have 4 of 38 reference labs with interface connectivity
- **All Data analysis is performed in Excel**
  - Limitations in storage, manipulation, reproducibility, and analysis of large amounts of data
  - Manual, inefficient, increased potential for error, quality issues
- **All Data delivered via email or placed on departmental shared drive for requestor or stakeholder to access**
  - No central repository for pathology data
  - Lack of standardization across reports

# Current State Pathology Division

## Locations




- Laboratory Locations

- MCC – Magnolia
- MKC - McKinley
- MWC – Wesley Chapel
- MIOMS – Advanced Diagnostics Laboratory
- MIP – International Plaza
- MMH – McKinley Hospital


- Future

- SouthShore 2025
- Speros 2026

# Current State Diagram - Clinical



# Current State Diagram – Financial, Research, Other




# Overview of Future State Strategy



- Foundational Data Infrastructure
  - Data Modeling
  - Data harmonization
- Interface Connectivity
  - Establish interfaces with all reference labs (*Utilization and Clinical data*)
    - Leveraging Atlas or Direct interface connectivity (FSI)
- Automation Software – leverage existing applications within our portfolio
  - Revenue [EMUE]
  - Clinical [HEP]
  - Business [ABBY, Automation Anywhere]
- Smart business systems
  - Automated Inventory Management systems to allow for better cost control and expense analysis
  - Scheduling software to be able automate FTO and FTA processes and resource allocation management
- Pathology Informatics
  - Continued improvement through diagnostic accuracy and informed decision-making
- Digital Pathology
  - Data analysis of complex and large data sets

# Future State



Multi-Phase approach to deliver a final product

- Phase 1 – Data Collection and Preparation
- Phase 2 – Data Analytics and Visualization
- Phase 3 – Data Model Development, Database Connectivity, Automation, and Performance Management
- Phase 4 – Continuous Improvement




# Future State - Diagram




# Current State vs. Future State



## Current State



## Future State



# Future State Advantages



- By following this multi-phase approach, the pathology laboratory division can effectively leverage business intelligence to
  - ***Increase*** performance
  - ***Enhance*** patient outcomes
  - ***Achieve*** cost reduction and cost avoidance
  - ***Improve*** Quality and Safety
  - ***Stay*** ahead of the competition
  - ***Create*** scalability
  - ***Comply*** with regulatory requirements

# Primary Goals



- Load additional Pathology data into Moffitt Cancer Analytics Platform (MCAP)
- Addition of required business intelligence resources within the Pathology Business Operations team
- Scalable and repeatable approach to data gathering and mining for all pathology data
  - Collection
  - Storage
  - Access
  - Analytics

# Overview of Tactical Plan



- Leverage Late Binding Approach
  - Flexibility: Adaptability to changes in data sources or business requirements without requiring extensive modifications to the data warehouse.
  - Reduced Complexity: Elimination of upfront, pre-defined data transformations, resulting in simpler data integration processes.
  - Timeliness: Provides timely access to integrated data, as transformations are performed dynamically at the time of data retrieval.
- Simultaneous Logical Model Build-Out
  - Both the logical and physical data models are developed simultaneously.
  - Data transformations and integrations are performed dynamically as data is accessed or requested by end-users or applications.
  - Benefits include:
    - Faster time to delivery: Allows for quicker implementation as data modeling and integration tasks are executed concurrently.
    - Flexibility: Enables adjustments to the logical model based on evolving business requirements and user feedback.



# Impediments & Challenges



- Project Prioritization
- Resource Capacity (Internal and External)
  - Required Partner Collaborators
    - Data Architect, Data Engineer, BI Developer, Project Manager, Data Quality Analyst, Business Analyst, MCAP Product Owner
- Reference Laboratory technology capabilities
- Sequential Logical Model Build-Out strategy
  - Inconsistencies in the data model
  - Increased complexity: Managing simultaneous development of logical and physical models may require more coordination and oversight.
  - Resource constraints: Requires sufficient resources and expertise to execute both tasks in parallel effectively.



# Phase 1 : Data Collection and Preparation



1. Identify all relevant data sources, both internal (e.g., laboratory information systems, electronic health records) and external (e.g., reference laboratory data)
  - a) This has been completed ✓
2. Develop data flows between information systems that do not currently exist
  - a) [Reference slide 13](#)
3. Store the data in a centralized repository, such as a data mart, for easy access and analysis
  - a) Leverage existing Database Management architecture, Snowflake
  - b) [Reference slide 14](#)
4. Clean and standardize the data to ensure consistency and accuracy
  - a) Current state processes already established in Excel
  - b) Leverage MCAP data that has already undergone (get verbiage from slide 7)
  - c) Would be migrated to Snowflake/Microsoft SQL
    - i. **Requires dedicated Pathology Business Intelligence Developer [New position]**

# Phase 1 : Data Collection and Preparation




## Information System Database Availability

System	Database Available in Data Warehouse
Cerner Millennium	Yes
Cerner Soarian Financials	Yes
Clinsys PowerPath	Yes
CGW	Partial
LabVantage	No
Atlas	No
Reference Labs	Partial



# Path BI Strategy



# Phase 2 : Data Analytics and Visualization



- Utilize data analytics tools to uncover insights and trends in the pathology data
  - Currently leveraging Microsoft Excel and PowerBI
- Implement dashboards and reports to visualize key performance indicators (KPIs)
  - Examples
    - Diagnostic accuracy
    - Test turnaround time (TAT)
    - Revenue and expenses
    - Quality assurance
  - Work with Business owners to identify the KPI's for each area
  - **Implementation of single repository for data visualization**
    - In process of migration to MoffittNet, [reference slide 16](#)
- Use predictive analytics to forecast future trends and inform tactical and strategic decision-making

# Phase 2 : Data Analytics and Visualization [Completed to Date]

- [Pathology Data Metrics and Analytics Moffittnet Page](#)



The screenshot shows the 'Pathology Data Metrics and Analytics' page on the MoffittNet platform. The page header includes the MoffittNet logo, a search bar, and navigation links for Home, Feed, Sites, People, and Apps. The page title is 'Pathology Data Metrics and Analytics' by Joshua Rivera, published on Dec 16, 2022, and edited on Apr 25, 2023. The page features a bar chart with four bars in blue, orange, green, and light blue, and a line graph with an orange line and white circular markers. A magnifying glass is positioned over the green bar, highlighting a specific data point. The page also displays 'Total views 390' and 'Viewed by 54%'.

# Phase 2 : Data Analytics and Visualization

[Layout]

---

- Pathology Division
  - ❑ Focused on Revenue and Expenses
- Advanced Diagnostics Laboratory
  - ❑ Clinical Productivity Data by laboratory information system (LIS)

- 
- Pathology Division
    - ChargeMaster with Volumes by CDM\_Hospital
    - Pathology Revenue and Usage Trending [*Excel*]
    - Pathology Billables by Cost Center
    - Pathology Billable Test Report [*Excel*]
      - **Note:** Being replaced with Pathology Billables by Cost Center effective July 2023
    - Pathology Year-to-date Revenue [*Excel*]
- 

- Advanced Diagnostics Laboratory
    - Clinical Genomic Workspace [CGW]
      - NGS TAT
      - NGS Volume
    - Cytogenetics Volume and TAT
    - LabVantage Turn Around Times
      - FISH TAT
      - Flow Cytometry TAT
      - HLA TAT
      - Molecular TAT
-

# Phase 2 : Data Analytics and Visualization

[Layout]

---

- Anatomical Pathology
  - Clinical productivity Data by laboratory information system (LIS)
  - Departmental productivity data

- 
- Anatomical Pathology
    - Anatomic Pathology Charge Volume
    - Anatomic Pathology Completed Case Volume
    - Autopsy Case TAT
    - Grossing Volume
    - Histology Case Progression [*Excel*]
    - Histology ER PR HER2 IHC ISH volume
    - Histo Lab Productivity
    - Materials Management
    - PowerPath Billing Exception Report
    - PowerPath Case Transfer Log Report
-

# Phase 2 : Data Analytics and Visualization

[Layout]

- Clinical Pathology

- Clinical productivity Data by Area and campus
- Clinical quality assurance data
- Clinical benchmark reporting

- Clinical Pathology
  - Blood Bank
    - BB Apheresis Platelets Volume
    - BB Cryo Volume
    - BB Total Plasma Volume
    - BB Random Platelets Volume
    - BB RBC Volume
  - Chemistry
    - Chem - Prechemo/STAT TAT [Detail]
    - Chem - Prechemo TAT data by month [Summary] [Excel]
  - Hematology
    - Hemo - Prechemo TAT
    - Hemo - Prechemo Volume
    - Hemo - PT/PTT TAT
  - Moffitt McKinley Hospital (MMH)
    - Chemistry (MMH)
      - MMH\_Chem\_PTH, HS TROP, LA [Excel]
      - MMH\_Chem\_STAT CMP [Excel]
    - Hematology (MMH)
      - MMH\_Heme\_STAT\_CBC [Excel]
    - Microbiology (MMH)
      - MMH Micro Molecular Panel Positive Rate [Excel]
      - MMH Micro Single test Positive Rate [Excel]
      - MMH Micro TAT\_COVID,MRSA,CDIF [Excel]
      - MMH Micro TAT\_RPGI panel,MEP by PCR [Excel]
    - Specimen Processing (MMH)
      - MMH\_SP\_Specimen Cancellation [Excel]

# Phase 2 : Data Analytics and Visualization

[Layout]


- Precision Medicine
  - ☐ Volumes
- Quality Assurance
  - ☐ Cases with Revisions

- 
- Precision Medicine
    - Precision Medicine Volume

- 
- Quality Assurance
    - Cases with Revisions [*Exce*]

# Phase 2 : Data Analytics and Visualization:

Microsoft PowerBI examples





# Microsoft PowerBI:

## Current Pathology PowerBI Library



Favorites **Browse**

Publish Tiles

Power BI Reports (28)

- AP Charge Volume
- Autopsy cases
- BB Apheresis PltsTotals
- BB Cryo Totals
- BB Plasma Totals
- BB Random PltsTotals
- BB RBC Totals
- Billables by Cost Center
- Case Transfer Log
- Case Volume\_Finalized Date
- Cases with Revision
- CGW Volumes
- Chargemaster with volumes by CDM\_Hospital
- Chargemaster with volumes by CDM\_professional
- CMP TAT and Volume PreChemo
- Cytogenetics Volume and TAT
- HEM PreChemo Volumes
- HistoLab Productivity
- Histology ER PR HER2 IHC ISH volume
- LabVantage Data
- Materials Management
- MIP Volumes
- Monthly grosser volume
- MWC to MCC
- PT PTT TAT and Volume
- Test Utilization of Labs with Small Volumes
- Test Utilization of Reference Labs
- Tracking Precision Medicine Charge Volumes

# Microsoft PowerBI example: LabVantage Productivity [Molecular]



Favorites Browse

File View Explore Refresh

Test	0	1	2	3	4	5	6	7	8	
BCELLGENE	0.27%	1.92%	10.71%	8.52%	9.89%	12.09%	13.19%	23.35%	10.4%	
BCRABLP190	0.18%	6.65%	8.27%	7.73%	17.45%	13.31%	17.81%	13.13%	10.7%	
BCRABLP210	0.34%	15.41%	20.31%	15.06%	15.06%	13.70%	12.27%	4.98%	1.5%	
BRAF V600E ddPCR		4.76%	11.90%	16.67%	11.90%	4.76%	14.29%	11.90%	9.5%	
BRAFMA	0.25%	4.70%	16.58%	16.83%	17.33%	25.00%	11.88%	4.70%	1.2%	
CD3/33 Post Trans Engraft		5.02%	15.99%	17.06%	15.65%	20.33%	15.38%	5.42%	2.2%	
CLL FISH Panel	0.19%	2.51%	37.64%	14.09%	27.41%	14.86%	2.32%	0.58%		
CTCCOUNT	2.24%	55.22%	12.69%	12.69%	11.19%	2.24%	2.24%	0.75%		
CYP2C19 Genotype		19.10%	21.11%	20.10%	11.06%	5.53%	9.55%	8.54%	3.0%	
Donor Pre-Engraft		5.83%	24.17%	20.00%	13.33%	15.00%	12.50%	5.00%		
EGFR Gene Analysis Idylla	1.85%	33.33%	25.31%	7.41%	19.75%	7.41%	2.47%	1.23%	0.6%	
EGFRMA	1.61%	11.29%	16.13%	20.97%	12.90%	11.29%	9.68%	11.29%	1.6%	
FISH for ALK		16.67%	16.67%			50.00%	16.67%			
FISH for AML: EVI1/3q26		5.97%	35.82%	17.91%	23.88%	14.93%		1.49%		
FISH for bcl-2			50.00%		50.00%					
FISH for bcl-2 FFPE		20.00%				20.00%	20.00%	40.00%		
FISH for bcl-6		14.29%			57.14%	28.57%				
FISH for bcl-6 FFPE				12.50%	12.50%		37.50%	12.50%	12.5%	
FISH for BCR/ABL1	0.22%	2.16%	44.49%	9.50%	28.08%	12.53%	2.16%	0.86%		
FISH for CHOP : DDIT3			28.57%		14.29%	14.29%	14.29%	14.29%		
FISH for c-myc		10.00%	40.00%		40.00%	10.00%				
FISH for c-myc FFPE							100.00%			
FISH for Del 11q23			33.33%		66.67%					
FISH for Del 13q14.3			66.67%		33.33%					
FISH for Del 20q12			50.00%	50.00%						
FISH for Del 5q31			63.64%	18.18%	18.18%					
FISH for Del 7q31			41.38%	24.14%	24.14%	10.34%				
FISH for EWSR1			25.00%		25.00%	12.50%		25.00%		
FISH for IgH/bcl-2		8.33%	41.67%	8.33%	12.50%	20.83%	4.17%	4.17%		
FISH for IgH/bcl-2 FFPE				22.22%	16.67%	38.89%		11.11%		
FISH for IgH/CCND1 FFPE		5.00%	15.00%	10.00%	5.00%	15.00%	15.00%	10.00%	15.0%	
FISH for IgH-bcl-1		6.35%	39.68%	6.35%	31.75%	11.11%	4.76%			
FISH for INV16		7.96%	43.36%	8.85%	26.55%	11.50%	1.77%			
<b>Total</b>	<b>0.00%</b>	<b>0.24%</b>	<b>6.24%</b>	<b>21.19%</b>	<b>12.35%</b>	<b>14.51%</b>	<b>15.04%</b>	<b>10.33%</b>	<b>6.89%</b>	<b>3.4%</b>

**Month**

Select all

Jul

Aug

Sep

Oct

Nov

Dec

**FY**

2023

**Lab**

Select all

FISH

Flow Cytometry

HLA

Molecular

**Sub Specialty**

Select all

CP

GI

GU

Molecular

**Test**

Select all

BCELLGENE

BCRABLP190

BCRABLP210

BRAF V600E ddPCR

BRAFMA

CD3/33 Post Trans Engraft

CLL FISH Panel

CTCCOUNT

CYP2C19 Genotype

**Sample Type**

Select all

Axillary Lymph Node

Biopsy, Bone

Biopsy, Brain

Biopsy, Gastric

Biopsy, Misc

Biopsy, Skin

Blood

Bone Marrow



# Microsoft PowerBI example: PowerPath Volume [Anatomical Pathology]



# Microsoft PowerBI example: PowerPath HistoLab Productivity [Anatomical Pathology]




Favorites Browse

Comments

File View Explore Refresh

**Microtomy Productivity by Hour of the Day**

Group ● H&E ● IHC ● Miscellaneous ● Special Stain



- CY  2024  2023  2024
- FY  2023  2024
- Month  Select all  Aug  Dec  Feb  Jan  Jul  Mar  Nov  Oct  Sep

- Group
- Control
  - Embedding
  - H&E
  - IHC
  - Miscellaneous
  - NA
  - Other
  - Special Stain


- User
- Search [ ]
- Select all
  - Aparicio, Vicky V
  - Arceo, Liliana M
  - Balbuena Ravelo, Jorge
  - Ballester, Betty
  - Castro, Ariel
  - Chavez, Becky
  - Gallagher, Carolyn
  - Garchar, Andrew
  - Garcia-Diaz, Veronica
  - Gonzalez Ferrer, Damaris
  - Jeanty, Medjine
  - Keles, Burak
  - Louro Roig, Reinaldo
  - Ozan Aslan, Hanife
  - Rivera, Carmen L
  - Salvatore, Bobbie
  - Soler De Zayas, Raquel
  - Sullivan, Vertessa-Ann P



# Microsoft PowerBI example: Blood Bank Apheresis Platelets Totals [Clinical Pathology]



# Microsoft PowerBI example: Reference Lab Utilization [*Clinical Pathology*]



## Phase 3 : Data Model Development, Database Connectivity, Automation, and Performance Management



- Create Data Model that encompasses all data sources using a Data Architect
- Create a physical data model that leverages existing models such as the one created for the *Financial Reporting Expansion* project in addition to the new data sources
- Develop key performance metrics and KPIs to track and monitor the performance of the pathology laboratory
  - *Already being established by working with key stakeholders in each area*
- Set up alerts to notify stakeholders of important changes and deviations from targets
  - *Personalized Subscriptions for automated delivery of data*
- Regularly review and analyze performance data to identify areas for improvement
  - *Leverage Monthly Quality Assurance meetings for KPI reporting and issue management*
  - *Dedicated Laboratory Data Management and Analysis meetings*
    - *Stakeholders from Anatomical, Clinical, Molecular, Quality Assurance, Research (Tissue Core)*

# Phase 4 : Continuous Improvement [Data Governance through PASC]




- Establish clear data governance policies and procedures that cover data access, use, and security. – In Process
- Assign roles and responsibilities for managing pathology data, including data owners, stewards, and custodians. – In Process
- Define data quality standards and establish processes for monitoring and maintaining data quality. – In Process
- Ensure compliance with legal and regulatory requirements, including data privacy and security laws. – In Process
- Implement a data classification scheme to classify pathology data according to its sensitivity, confidentiality, and criticality. – In Process
- Control access to pathology data based on the principle of least privilege, granting access only to those who need it to perform their job functions. - COMPLETED
- Ensure that data is backed up regularly and that disaster recovery and business continuity plans are in place to protect against data loss or system failure.
- Conduct regular data audits to identify data quality issues, security breaches, and compliance violations.
- Establish a data retention policy that defines how long pathology data should be kept and when it can be safely deleted or destroyed.
- Ensure that all stakeholders understand their roles and responsibilities in maintaining the integrity and security of pathology data, and provide training and education as needed to promote data governance awareness and compliance.





## Pathology Business Operations Organizational Chart – FUTURE

Phase 4 :  
Continuous  
Improvement





# Phase 4 : Continuous Improvement

- Incorporate feedback from stakeholders, including patients, healthcare providers, and laboratory staff, to identify areas for improvement
- Use the insights gained from data analysis to continuously refine and improve processes, procedures, and technologies within the pathology laboratory
- **Foster a culture of data-driven decision-making and continuous improvement**



# Phase 5 – Long Term Pathology BI Future

- Fully integrated data visualization solution that can provide in depth clinical analysis
  - Examples of reports
    - Watchful Test Ordering
    - Duplicate Lab Orders
    - PPID Compliance for Lab Specimen
    - Incorrect Test Combinations Ordered
    - Diagnostic Test Distribution
    - Incorrect Ordering Frequency
    - Physician Sendout Ordering Patterns
    - Physician Ordering benchmarks
    - Diagnostic Trends of Ordered Tests
    - Average Sendout Turn Around Time Volume by Performing Lab



Questions?

